Literature DB >> 29359892

Implementation of the Provision of the Comprehensive Addiction and Recovery Act of 2016 Relating to the Dispensing of Narcotic Drugs for Opioid Use Disorder. Final rule.

.   

Abstract

The Comprehensive Addiction and Recovery Act (CARA) of 2016, which became law on July 22, 2016, amended the Controlled Substances Act (CSA) to expand the categories of practitioners who may, under certain conditions on a temporary basis, dispense a narcotic drug in Schedule III, IV, or V for the purpose of maintenance treatment or detoxification treatment. Separately, the Department of Health and Human Services, by final rule effective August 8, 2016, increased to 275 the maximum number of patients that a practitioner may treat for opioid use disorder without being separately registered under the CSA for that purpose. The Drug Enforcement Administration (DEA) is hereby amending its regulations to incorporate these statutory and regulatory changes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29359892

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  3 in total

1.  Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.

Authors:  Babak Tofighi; Arthur Robin Williams; Chemi Chemi; Selena Suhail-Sindhu; Vicky Dickson; Joshua D Lee
Journal:  Subst Use Misuse       Date:  2019-08-20       Impact factor: 2.164

2.  Evidence-Based Treatment of Young Adults With Substance Use Disorders.

Authors:  Scott E Hadland; Amy M Yule; Sharon J Levy; Eliza Hallett; Michael Silverstein; Sarah M Bagley
Journal:  Pediatrics       Date:  2021-01       Impact factor: 7.124

3.  Implementation of a Medication for Addiction Treatment (MAT) and Linkage Program by Leveraging Community Partnerships and Medical Toxicology Expertise.

Authors:  Gillian A Beauchamp; Lexis T Laubach; Samantha B Esposito; Ali Yazdanyar; Paige Roth; Priyanka Lauber; Jamie Allen; Nathan Boateng; Samantha Shaak; David B Burmeister
Journal:  J Med Toxicol       Date:  2020-11-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.